C-o-group (e.g., Alcohol, Alcoholate, Etc.) Doai Patents (Class 514/724)
  • Patent number: 10220006
    Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GB S), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodeg
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: March 5, 2019
    Assignee: Mitochon Pharmaceuticals, Inc.
    Inventors: Robert Alonso, John Gerard Geisler
  • Patent number: 10071233
    Abstract: An applicator for treating skin conditions includes at least one treatment composition component and a discontinuity identification component. The at least one treatment composition component is configured to selectively deposit a treatment composition at a deposit location on the portion of skin. The discontinuity identification component is operably coupled to an electromagnetic energy detector. The discontinuity identification component includes circuitry configured to monitor a level of the one or more parameters as the applicator traverses the portion of skin and to control the at least one treatment composition component to selectively deposit the treatment composition to the deposit location on the portion of skin based on one or more inputs indicative of a decrease in reflection of an electromagnetic energy interrogation stimulus from the portion of skin at the deposit location.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 11, 2018
    Assignee: L'OREAL
    Inventors: Vincenzo Casasanta, III, Joseph W. Grez, Zane Bowman Allen Miller
  • Patent number: 9980483
    Abstract: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 29, 2018
    Assignee: Ecolab USA Inc.
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Patent number: 9976097
    Abstract: The invention relates generally to a charcoal ignition fluid that is composed of a cellulose ether polymer, butanol, and water. The charcoal ignition fluid has performance characteristics similar to petroleum distillate but is more sustainable. Additionally, the charcoal ignition fluid can include ethanol and/or an alcohol to reduce the water content. Moreover, the charcoal ignition fluid can include an acetate salt to increase the visible flame for safety purposes. The charcoal ignition fluid may also include an organic ester to enhance the odor of the ignition fluid.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 22, 2018
    Assignee: INNOVERDANT, LLC
    Inventor: Paul Ray Parrott
  • Patent number: 9974755
    Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodege
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: May 22, 2018
    Assignee: Mitochon Pharmaceuticals, Inc.
    Inventors: Robert Alonso, John Gerard Geisler
  • Patent number: 9962323
    Abstract: Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with without a tacky residue upon drying.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: May 8, 2018
    Assignee: Ecolab USA Inc.
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Patent number: 9956148
    Abstract: The present invention provides an oil-in-water emulsion cosmetic that is excellent in the resilient and supple (in other words, firm, tensional, and elastic) feel and also excellent in the softness and moisturizing effect. The oil-in-water emulsion cosmetic of the present invention is characterized by comprising the following components: (A) 0.1 to 5 mass % of hydrogenated polyisobutene with a number average molecular weight of 2000 to 3000, (B) 0.1 to less than 1 mass % of higher alcohol, (C) 1 to 25 mass % of an oil component, (D) 0.3 to 5 mass % of surfactant, (E) 0.05 to 5 mass % of water-soluble thickener, and (F) an aqueous component, wherein the blending quantity of nonpolar oil is 30% or lower of the total amount of component (C).
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: May 1, 2018
    Assignee: Shiseido Company, Ltd.
    Inventors: Ayako Ibe, Yuji Matsushita
  • Patent number: 9943080
    Abstract: A self-generated antimicrobial alcoholic foam prepared by combining an alcoholic pre-mix comprising at least 50 wt. % of a lower alcohol, based upon the total weight of the alcoholic pre-mix, at least one acidic component, and at least one waxy component; and an aqueous pre-mix comprising a carbonate. A dispenser and a two-part refill for a dispenser are also provided.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 17, 2018
    Assignee: GOJO Industries, Inc.
    Inventors: Mitchell Jared Cohen, James Harvey Eberts, III, Evan David Hillman
  • Patent number: 9907776
    Abstract: The present invention relates to a composition for preventing or treating a psychiatric disorder comprising a phenyl carbamate compound and a method for preventing or treating a psychiatric disorder therewith. The present invention provides anti-anxiety activity and protections against seizure and bipolar disorder, such that it may be effectively used for preventing or treating various psychiatric disorders related to mood disorder or resulting convulsion.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 6, 2018
    Assignee: Bio-Pharm Solutions, Co., Ltd.
    Inventor: Yong Moon Choi
  • Patent number: 9901563
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: February 27, 2018
    Assignee: DELMAR PHARMACEUTICALS, INC.
    Inventor: Dennis M. Brown
  • Patent number: 9763896
    Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodege
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 19, 2017
    Assignee: Mitochon Pharmaceuticals, Inc.
    Inventors: Robert Alonso, John Gerard Geisler
  • Patent number: 9687466
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 27, 2017
    Assignee: DELMAR PHARMACEUTICALS, INC.
    Inventors: Jeffrey A. Bacha, Dennis Brown, Sandra Dunn, Anne Steinø
  • Patent number: 9662341
    Abstract: A two-part aqueous composition for treating skin ailments, such as acne vulgaris, includes an acidic part having salicylic acid and an ?-hydroxy acid, and an alkaline part having an alkaline nitrite salt. The ?-hydroxy acid is preferably glycolic acid, lactic acid, malic acid, mandelic acid or a combination thereof. The alkaline nitrite salt is preferably sodium nitrite. The acidic part and the alkaline part are an acidic aqueous solution and an alkaline aqueous solution, respectively, which may either be mixed with one another then applied to an affected portion of a patient's skin or, alternatively, may be sequentially applied to the affected portion of the patient's skin, preferably within 15 minutes of one another.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: May 30, 2017
    Assignee: Kantian Sciences Corporation
    Inventor: Robert D. Kross
  • Patent number: 9439841
    Abstract: Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with without a tacky residue upon drying.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: September 13, 2016
    Assignee: Ecolab USA Inc.
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Patent number: 9314419
    Abstract: An oral care composition with reduced bitterness containing polyquaternium-2, polyquaternium-17, and/or polyquaternium-18.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: April 19, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Yakang Lin, Koti Sreekrishna, John Christian Haught
  • Patent number: 9259400
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 16, 2016
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado, Khalid El Sayed
  • Patent number: 9040103
    Abstract: The present invention concerns various compositions comprising the essential oil of Origanum compactum or of Aniba rosaeodora or one of their constituents, preferably a major constituent, for use in the targeted treatment and prevention of keratoses in the transformation phase and of carcinomas originating from these keratoses, and more particularly of keratoses induced by solar radiation on the skin of a subject. More particularly, the present invention concerns compositions based on the essential oil of oregano or of rosewood, or on linalool, thymol or carvacrol.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 26, 2015
    Assignees: L'Oreal, Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Laurent Marrot, Jérémie Soeur, Meng-Er Huang
  • Patent number: 9034928
    Abstract: The present embodiments disclose the preparation of hyperpolarized 13C dialkyl succinate compounds and hyperpolarized 13C dialkyl fumarate compounds and their use in real time, in vivo metabolic imaging of the TCA cycle.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 19, 2015
    Assignee: IMAGNX, Inc.
    Inventors: Niki Zacharias Millward, Pratip Bhattacharya
  • Patent number: 9034916
    Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: May 19, 2015
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Won Gon Kim, Baek Soo Han, Kyoung Shim Kim, Kwang Soo Kim, Young Mi Kang, Yu Jin Kim, Chun Hyung Kim, Mi Jin Sohn, Hoe Yune Jung
  • Publication number: 20150133371
    Abstract: The present invention relates to a method or composition for glycemic control in a subject, which is effective for treating diabetes mellitus, comprising administering the subject with a pharmaceutical composition comprising a therapeutically effective amount of an aliphatic alcohol having a general formula of CH3(CH2)nCH2OH, wherein n is an integer from 10 to 40, such as tetracosanol, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 14, 2015
    Applicant: National Dong Hwa University
    Inventors: Ching-Feng Weng, Chin-piao Chen, Yi-Chen Chia, Chia-Yu Hsu
  • Patent number: 9023406
    Abstract: The present invention is directed to compositions and processes for their use that ameliorate the appearance of bruises, making them less cosmetically unappealing. The composition functions by acting both as a humectant and occlusive agent attracting water, returning the skin surface to a smooth state and holding water in place. The re-establishment of a homeostatic state in the skin results in a rapid dissipation of the negative cosmetic effects of the bruise on the skin.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: May 5, 2015
    Assignee: Dr. Holmquist Healthcare, LLC
    Inventors: Bruce A. Cranner, Anne-Marie T. Karp, C. Scott Danos
  • Publication number: 20150111918
    Abstract: Methods for treating a patient using therapeutic immune system neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves proximate a vessel or duct of an immune system organ using an intravascularly or intraluminally positioned therapeutic element. One or more measurable physiological parameters corresponding to an immune system disorder, a condition associated with sympathetic activity in an immune system organ, or a condition associated with central sympathetic activity in the patient can thereby be reduced.
    Type: Application
    Filed: March 7, 2013
    Publication date: April 23, 2015
    Inventors: Paul Sobotka, Neil Barman
  • Publication number: 20150111972
    Abstract: There is provided a composition comprising: (a) from about 60 to about 98% by weight of one or more alcohols; (b) from about 0.5 to about 20% by weight of one or more alkyl cellulose derivatives, wherein each alkyl is optionally substituted with one or more OH, O-alkyl, O-hydroxyalkyl and/or O-alkoxyalkyl; (c) from about 1 to about 25% by weight of one or more carboxylic acid salts; and (d) from 0 to about 30% by weight of water. There is also provided uses, processes for manufacture, methods and products relating to the same.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 23, 2015
    Inventors: David W. Knight, Ian R. Morgan
  • Patent number: 9011829
    Abstract: Perfume compositions comprise between 10% and 30% in total weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A ingredients in the aggregate percentage of Group B ingredients present must be at least equal to the expression (2*/10?A %) where A % is the total percentage of Group A ingredients in the composition.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: April 21, 2015
    Assignee: Givaudan Nederland Services B.V.
    Inventors: Keith Douglas Perring, Michael Gordon Evans, Alan Forbes Provan, David Jonathan Bradshaw, John Martin Behan
  • Publication number: 20150105349
    Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.
    Type: Application
    Filed: August 19, 2013
    Publication date: April 16, 2015
    Inventor: Edward T. Wei
  • Patent number: 9006292
    Abstract: The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 14, 2015
    Assignee: NanoRx, Inc.
    Inventor: Palayakotai R. Raghavan
  • Patent number: 8999399
    Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
    Type: Grant
    Filed: November 14, 2009
    Date of Patent: April 7, 2015
    Assignee: Bose Chemie GmbH
    Inventors: Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
  • Publication number: 20150080478
    Abstract: A method for preparing an antimicrobial alcoholic foam composition by combining two or more pre-mix compositions. A first pre-mix composition is primarily alcoholic comprises an alcohol, an acidic component, and a waxy component. A second pre-mix composition is primarily aqueous comprises water and a carbonate. An antimicrobial alcoholic foam composition that does not require added air or aerosol propellant is also provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Inventors: Mitchell Jared Cohen, James Harvey Eberts, III, Evan David Hillman
  • Patent number: 8980951
    Abstract: Bicyclic sesquiterpene compounds exhibiting antifungal characteristics are formulated into antifungal compositions for use in the treatment of fungal infections in humans, animals, and plants. Particularly, sesquiterpene alcohols derived from drimane have been discovered to possess broad-spectrum antifungal characteristics. Exemplary antifungal sesquiterpene compounds include albicanol and drimenol, which have been shown effective against a number of pathogenic fungi.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: March 17, 2015
    Assignee: Kansas State University Research Foundation
    Inventors: Govindsamy Vediyappan, Duy H. Hua
  • Publication number: 20150065945
    Abstract: Methods for treating a patient using therapeutic spinal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves of one or more targeted organs proximate one or more dorsal root ganglia, stellate ganglia, vertebral ganglia, or cervical ganglia of the nerves using an intravascularly-positioned therapeutic element. One or more measurable physiological parameters corresponding to at least one condition associated with sympathetic activity in the targeted organs and/or central sympathetic activity in the patient can thereby be reduced.
    Type: Application
    Filed: March 7, 2013
    Publication date: March 5, 2015
    Inventors: Denise Zarins, Sean Ward
  • Patent number: 8969297
    Abstract: Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: March 3, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Laurence M. Katz
  • Publication number: 20150056298
    Abstract: According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Inventors: Bobak Robert Azamian, Scott Bradley Vafai
  • Patent number: 8962694
    Abstract: Compositions suitable for the control of pest amphibian species are described. More particularly, compositions for killing amphibians are described that comprise: (i) a xylenol compound or derivative according to formula (I) wherein R1, R2, R3, R4 and R5 are each independently selected from hydrogen, hydroxyl, halogen, —NH3 and C1-6 alkyl, and —R6—NH2, —R6—ONH2, —R6—NO2, and —R6—PO4, wherein R6 is C1-6 alkyl, and X is selected from hydrogen, halogen and C1-6 alkyl, or a salt thereof, and (ii) ethanol and optionally, (iii) methanol and/or at least one C3-6 alcohol. Methods for killing amphibians include contacting the amphibian with said compositions. Kits are described wherein said xylenol compounds and ethanol and optionally methanol and/or at least one C3-6 alcohol may be administered simultaneously or sequentially.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: February 24, 2015
    Assignee: Pestat Pty Ltd.
    Inventors: David James Dall, Joan Dawes
  • Patent number: 8962693
    Abstract: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: February 24, 2015
    Assignee: Hormos Medical Ltd.
    Inventors: Risto Santti, Tomi Streng
  • Patent number: 8957106
    Abstract: A proliferation of cells can be reduced by contacting the cells with a compound having formula (I) where R and R? are each alkyl groups, R? is hydrogen or an alkyl group and X3, X4 and X5 are each independently selected from the group consisting of hydrogen, benzyl, t-butyldimethylsiloxy radical and triphenylmethyl. Accordingly, compounds of formula (I) can be used for treatment of tumors including melanoma. Also a secretion of a matrix metalloproteinase (MMP) enzyme by cells can be reduced by contacting the cells with the compound having formula (I). Accordingly, compounds of formula (I) can be used for treatment physiological conditions associated with an elevated MMP level, such as tumors.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: February 17, 2015
    Assignee: The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Raymond Dwek, Wanda Buzgariu, Anca Hirtopeanu, Robert Moriarty, Gabriela Negroiu, Norica Nichita, Livia Zdrentu, Nicole Zitzmann
  • Patent number: 8952075
    Abstract: Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: February 10, 2015
    Assignee: Poly-Med, Inc.
    Inventor: Shalaby W. Shalaby
  • Patent number: 8952062
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 10, 2015
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Publication number: 20150038441
    Abstract: The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal.
    Type: Application
    Filed: December 21, 2011
    Publication date: February 5, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Joachim Karle, Reinhard Seffner
  • Patent number: 8945595
    Abstract: The disclosure provides compounds useful as insect repellents and compositions comprising such repellents. The disclosure further provides insect traps.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: February 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Anandasankar Ray, Stephanie Lynn Turner
  • Patent number: 8940797
    Abstract: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: January 27, 2015
    Assignee: Ecolab USA Inc.
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Publication number: 20150025156
    Abstract: Antimicrobial and foamable alcoholic compositions, where the compositions include at least about 40 wt. % of a C1-4 alcohol and one or more silane surfactants selected from (1) zwitterionic silane surfactants, (2) polyalkoxylated silane surfactants that contain at least one silane group and at least one polyalkylene oxide chain.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Evan D. Hillman, Daniel J. Lacks, Mitchell J. Cohen
  • Publication number: 20150011651
    Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.
    Type: Application
    Filed: January 13, 2014
    Publication date: January 8, 2015
    Applicant: PROTIA, LLC
    Inventors: Anthony W. Czarnik, Jeffrey A. McKinney
  • Publication number: 20150011652
    Abstract: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Publication number: 20140369758
    Abstract: The instant invention relates to methods for increasing or promoting microbial activity in soil selected for treatment.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Applicant: ORO AGRI, INC.
    Inventors: Erroll Melvyn Pullen, Melvin Donovan Pullen
  • Publication number: 20140364509
    Abstract: Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with without a tacky residue upon drying.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 11, 2014
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Publication number: 20140357727
    Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides fatty acyl-CoA reductase (FAR) variant enzymes, polynucleotides encoding the FAR variant enzymes, and vectors and host cells comprising polynucleotides encoding the FAR variant enzymes.
    Type: Application
    Filed: December 13, 2012
    Publication date: December 4, 2014
    Inventors: Louis A. Clark, Kristian Karlshoej, Patricia Choudhary
  • Patent number: 8901172
    Abstract: A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition comprising or consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition to below 4.6. Topical administration of the composition is preferred and is effective in treating lesions associated infections by viruses such as Herpes simplex. Nasal deliverable forms are effective in treating symptoms due to viruses that cause the common cold. Pharmaceutical compositions for use in the present method are provided.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: December 2, 2014
    Assignee: Topical Rememdy, LLC
    Inventors: Thomas Konowalchuk, Jack Konowalchuk
  • Publication number: 20140348944
    Abstract: This invention relates to a “high lower alcohol content”(>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.
    Type: Application
    Filed: February 24, 2014
    Publication date: November 27, 2014
    Applicant: Deb Worldwide Healthcare Inc.
    Inventors: Maria Teresa Fernandez de Castro, Bruce Michael Koivisto, Francisco Munoz
  • Patent number: 8877818
    Abstract: Compositions (3) and methods of using such compositions (3) to condition, clean, or disinfect the flow path of a conduit (8) of a microfluidic devices (16), such as flow cytometers or liquid chromatographs.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: November 4, 2014
    Assignees: XY, LLC, CHD Bioscience, Inc
    Inventors: Edwin Dean Neas, Jerald Edward Kuiken, John Louis Schenk, Thomas Boyd Gilligan
  • Patent number: 8865232
    Abstract: The present invention relates to a method for treating a disorder chosen from ocular Demodex, Demodex-induced blepharitis, rosacea, acne, and meibomian gland dysfunction in a patient in need thereof, comprising administering to the patient a compositions comprising a therapeutically effective amount of a substance chosen from at least one of an isoprenoidal essential oil such as Tea Tree Oil; Terpinen-4-ol; (+)-Carvone; alpha-Terpineol; Cardinene; d-Carvone; 1-Carvone; gamma-Terpinene; alpha-Terpinene; 1,8-Cineole; alpha-Terpineol; para-Ci mene; alpha-Pinene; Limonene; (R)-(+)-Limonene; alpha-Thugene; Eucalyptol; (+)-Ledene; Cuminic Aldehyde; and Myrcene; the administration comprising contacting or scrubbing an affected area of skin or hair, or eyelid margin and lashes of the patient with the composition; also disclosed are a method for treating mange and mite infestations on a mammalian animal; and kits for in-office and at home treatments of the disorders.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: October 21, 2014
    Assignee: TissueTech, Inc.
    Inventors: Ying-Ying Gao, Scheffer Tseng